Nifedipine chemical structure
Find information on thousands of medical conditions and prescription drugs.

Adalat

Nifedipine (brand name Adalat and Procardia) is a dihydropyridine calcium channel blocker. Its main uses are in angina pectoris (especially Prinzmetal angina) and hypertension, although a large number of other uses have recently been found for this agent, such as Raynaud's phenomenon, premature labor, and painful spasms of the esophagus in cancer patients.

Home
Diseases
Medicines
A
8-Hour Bayer
Abacavir
Abamectin
Abarelix
Abciximab
Abelcet
Abilify
Abreva
Acamprosate
Acarbose
Accolate
Accoleit
Accupril
Accurbron
Accure
Accuretic
Accutane
Acebutolol
Aceclidine
Acepromazine
Acesulfame
Acetaminophen
Acetazolamide
Acetohexamide
Acetohexamide
Acetylcholine chloride
Acetylcysteine
Acetyldigitoxin
Aciclovir
Acihexal
Acilac
Aciphex
Acitretin
Actifed
Actigall
Actiq
Actisite
Actonel
Actos
Acular
Acyclovir
Adalat
Adapalene
Adderall
Adefovir
Adrafinil
Adriamycin
Adriamycin
Advicor
Advil
Aerobid
Aerolate
Afrinol
Aggrenox
Agomelatine
Agrylin
Airomir
Alanine
Alavert
Albendazole
Alcaine
Alclometasone
Aldomet
Aldosterone
Alesse
Aleve
Alfenta
Alfentanil
Alfuzosin
Alimta
Alkeran
Alkeran
Allegra
Allopurinol
Alora
Alosetron
Alpidem
Alprazolam
Altace
Alteplase
Alvircept sudotox
Amantadine
Amaryl
Ambien
Ambisome
Amfetamine
Amicar
Amifostine
Amikacin
Amiloride
Amineptine
Aminocaproic acid
Aminoglutethimide
Aminophenazone
Aminophylline
Amiodarone
Amisulpride
Amitraz
Amitriptyline
Amlodipine
Amobarbital
Amohexal
Amoxapine
Amoxicillin
Amoxil
Amphetamine
Amphotec
Amphotericin B
Ampicillin
Anafranil
Anagrelide
Anakinra
Anaprox
Anastrozole
Ancef
Android
Anexsia
Aniracetam
Antabuse
Antitussive
Antivert
Apidra
Apresoline
Aquaphyllin
Aquaphyllin
Aranesp
Aranesp
Arava
Arestin
Arestin
Argatroban
Argatroban
Argatroban
Argatroban
Arginine
Arginine
Aricept
Aricept
Arimidex
Arimidex
Aripiprazole
Aripiprazole
Arixtra
Arixtra
Artane
Artane
Artemether
Artemether
Artemisinin
Artemisinin
Artesunate
Artesunate
Arthrotec
Arthrotec
Asacol
Ascorbic acid
Asmalix
Aspartame
Aspartic acid
Aspirin
Astemizole
Atacand
Atarax
Atehexal
Atenolol
Ativan
Atorvastatin
Atosiban
Atovaquone
Atridox
Atropine
Atrovent
Augmentin
Aureomycin
Avandia
Avapro
Avinza
Avizafone
Avobenzone
Avodart
Axid
Axotal
Azacitidine
Azahexal
Azathioprine
Azelaic acid
Azimilide
Azithromycin
Azlocillin
Azmacort
Aztreonam
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Express Scripts, Medco praise generics for drug trend slowdown
From Drug Cost Management Report, 7/11/03

Express Scripts reports that its first-quarter 2003 drug trend slowed to 11.3%, compared with 16.9% in the same quarter of 2002. The PBM attributes the deceleration to:

* Increased acceptance and utilization of generic drugs by members;

* A mild flu season, with fewer antihistamines and cough-and-cold remedies used;

* Reduced utilization of estrogen drugs for hormone replacement therapy due to publicity about safety concerns last year.

Of these factors, generic drug utilization has the greatest potential for continued impact on the drug trend, the PBM says. During the first quarter of 2003, 47% of all prescription claims processed by Express Scripts were for generic drugs, up from 43% a year earlier. Greater use of generic drugs reduced the dollar outlay for prescription drugs by 3.2% during the first quarter and, for all of 2002, by 2.1%.

Express Scripts says that brand-name drugs representing $32.3 billion in U.S. sales are due to expire in the next five years, including Monopril, Nolvadex, Cipro and Celexa (see figure 1, page 3).

Despite the impact of generic utilization, the trend in certain categories remained high. Express Scripts said spending on blood pressure medications increased by 10.6% during the first quarter, cholesterol medications rose by 14.1%, and diabetes meds by 14.5%.

For the entire year of 2002, Express Scripts reports prescription drug spending for its clients increased 18.5% to $585.60 per member per year, from $494.20 in 2001. The company forecasts a 15.5% increase in drug spending for 2003.

In its recently released "Drug Trend Report," Medco Health Solutions also cites generic opportunities in the coming years--for those plans that are proactive. Classes to watch include nonsedating antihistamines (NSAs) and selective serotonin reuptake inhibitor (SSRI) antidepressants.

Taking advantage of generic opportunities as they occur is imperative, say PBMs, because other factors will continue to boost spending on prescription drugs. Medco says drugs now in the pipeline may account for up to 40% of the drug trend in the next few years. According to Medco's report, there are some 166 new drug applications awaiting FDA approval, and as many as 111 of them are potential blockbusters--with expected sales of more than $500 million per year.

Information: Steve Littlejohn, Express Scripts, (314) 702-7173; and Anne Smith, Medco Health Solutions, (201) 269-5984.

COPYRIGHT 2003 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group

Return to Adalat
Home Contact Resources Exchange Links ebay